Free Trial

CSL (CSLLY) Stock Forecast & Price Target

CSL logo
$93.76
-1.19 (-1.25%)
(As of 10/31/2024 ET)

CSL - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
1

Based on 1 Wall Street analysts who have issued ratings for CSL in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 1 analysts, 1 has given a strong buy rating for CSLLY.

Consensus Price Target

N/A

Get the Latest News and Ratings for CSLLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CSL and its competitors.

Sign Up

CSLLY Analyst Ratings Over Time

TypeCurrent Forecast
11/1/23 to 10/31/24
1 Month Ago
10/2/23 to 10/1/24
3 Months Ago
8/3/23 to 8/2/24
1 Year Ago
11/1/22 to 11/1/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
N/A
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
N/A
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
N/A
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
N/A
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus Rating
Strong Buy
Strong Buy
N/A
Buy

CSLLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CSLLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CSL Stock vs. The Competition

TypeCSLMedical CompaniesS&P 500
Consensus Rating Score
4.00
2.79
2.50
Consensus RatingStrong BuyModerate BuyHold
Predicted UpsideN/A16,648.92% Upside10.63% Upside
News Sentiment Rating
Neutral News

See Recent CSLLY News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/13/2024Macquarie
2 of 5 stars
D. Bailey
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
11/10/2022Credit Suisse Group
2 of 5 stars
 UpgradeNeutral ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:46 PM ET.


Should I Buy CSL Stock? CSLLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 20, 2024. Please send any questions or comments about these CSL pros and cons to contact@marketbeat.com.

CSL
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CSL Limited:

  • CSL Limited has a diverse product portfolio including plasma products, gene therapies, recombinants, influenza-related products, and products in therapeutic areas like iron deficiency and nephrology.
  • Recent short interest data shows a significant decline, indicating potential positive market sentiment towards CSL Limited.
  • CSL Limited's stock price has been relatively stable, with a 50-day simple moving average of $101.07 and a 200-day simple moving average of $97.29.
  • CSL Limited operates globally, providing exposure to multiple markets and reducing geographic risk.
  • Analysts have given CSL Limited a "strong-buy" rating, suggesting confidence in the company's future performance.

CSL
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CSL Limited for these reasons:

  • CSL Limited operates in the pharmaceutical industry, which can be subject to regulatory challenges and pricing pressures.

CSLLY Forecast - Frequently Asked Questions

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CSL in the last twelve months. There is currently 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" CSLLY shares.

According to analysts, CSL's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, CSL's stock had 1 upgrade by analysts.

CSL has been rated by research analysts at Macquarie in the past 90 days.

Analysts like CSL more than other "medical" companies. The consensus rating for CSL is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CSLLY compares to other companies.


This page (OTCMKTS:CSLLY) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners